Kymera Therapeutics (KYMR) EBIT (2019 - 2026)

Kymera Therapeutics (KYMR) has reported EBIT for 8 consecutive years, with -$84.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBIT fell 13.07% year-over-year to -$84.2 million; the TTM figure through Mar 2026 stood at -$359.1 million (down 29.08% YoY), while the FY2025 annual figure was -$349.4 million, down 33.54% from the prior year.
• EBIT advanced to -$84.2 million in Q1 2026 per KYMR's latest filing, from -$97.9 million in the prior quarter.
• Across five years, EBIT topped out at -$19.3 million in Q4 2023 and bottomed at -$97.9 million in Q4 2025.
• Historically, EBIT has averaged -$60.1 million across 5 years, with a median of -$57.5 million in 2023.
• Annual changes were most pronounced in 2023 — EBIT surged 50.01% — and 2024, when it slumped 318.16%.
• Kymera Therapeutics' EBIT stood at -$38.6 million in 2022, then soared by 50.01% to -$19.3 million in 2023, then plunged by 318.16% to -$80.8 million in 2024, then dropped by 21.23% to -$97.9 million in 2025, then climbed by 14.04% to -$84.2 million in 2026.
• Business Quant data shows KYMR's EBIT at -$84.2 million in Q1 2026, -$97.9 million in Q4 2025, and -$92.5 million in Q3 2025.